FDA OK’s IL-17As for nr-axSpA, But Few See Changes Ahead With Chart: Current Market Access to Ankylosing Spondylitis Medications

The FDA’s approvals of two interleukin-17A (IL-17A) antagonists to treat active non-radiographic axial spondyloarthritis (nr-axSpA) give providers new options for patients who are intolerant of non-steroidal anti-inflammatory medications (NSAIDs) and other therapies.

But the FDA’s decision to greenlight Eli Lilly and Co.’s Taltz (ixekizumab) and Novartis Pharmaceuticals Corp.’s Cosentyx (secukinumab) for the condition are unlikely to shake up plan formularies, since IL-17As currently are considered third-line treatments for the condition, PBM insiders say.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

iv-therapy
February 8

Incorporating Pharmacy Spending in Value-Based Payment Models Remains Challenging

READ MORE
pills-on-bills
February 8

As Reform Efforts Persisted, PBM Trade Association Set Its Lobbying Record in 2023

READ MORE
optum
February 8

Direct-to-Consumer Prescribing Could Have Downsides

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today